(S)-2-(4-((R)-4-(2,4-Diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic Acid

ID: ALA453089

PubChem CID: 135924168

Max Phase: Preclinical

Molecular Formula: C20H25N5O7

Molecular Weight: 447.45

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  Nc1nc(N)c(CCC[C@@H](O)c2ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc2)c(=O)[nH]1

Standard InChI:  InChI=1S/C20H25N5O7/c21-16-12(18(30)25-20(22)24-16)2-1-3-14(26)10-4-6-11(7-5-10)17(29)23-13(19(31)32)8-9-15(27)28/h4-7,13-14,26H,1-3,8-9H2,(H,23,29)(H,27,28)(H,31,32)(H5,21,22,24,25,30)/t13-,14+/m0/s1

Standard InChI Key:  OGTRQJJZWHQCBC-UONOGXRCSA-N

Molfile:  

     RDKit          2D

 32 33  0  0  0  0  0  0  0  0999 V2000
    5.7458  -10.5833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7458  -11.4083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4579  -11.8167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1699  -11.4083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1699  -10.5833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4579  -10.1667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0302  -10.1729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0277   -9.3479    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7410   -8.9333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4567   -9.3437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1699   -8.9292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8837   -9.3449    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5948   -8.9338    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5967   -8.1084    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8811   -7.6958    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.1638   -8.1086    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8823  -10.1699    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.3115   -7.6965    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.4481   -7.6982    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.8837  -11.8219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8825  -12.6469    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.5988  -11.4104    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.3127  -11.8239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0278  -11.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7416  -11.8260    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.0289  -10.5875    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.3115  -12.6489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0254  -13.0625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0242  -13.8875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7380  -14.3010    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.3091  -14.2989    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.3169  -10.5875    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
 14 15  2  0
 15 16  1  0
  7  8  1  0
 12 17  2  0
  1  6  1  0
 14 18  1  0
  8  9  1  0
 16 19  1  0
  2  3  1  0
  4 20  1  0
  9 10  1  0
 20 21  2  0
  3  4  2  0
 20 22  1  0
 10 11  1  0
 22 23  1  0
 11 12  1  0
 23 24  1  0
  4  5  1  0
 24 25  1  0
  5  6  2  0
 24 26  2  0
 23 27  1  6
  1  7  1  0
 27 28  1  0
  1  2  2  0
 28 29  1  0
 11 16  2  0
 29 30  1  0
 12 13  1  0
 29 31  2  0
 13 14  1  0
  7 32  1  6
M  END

Alternative Forms

  1. Parent:

    ALA453089

    ---

Associated Targets(Human)

GART Tclin GAR transformylase (531 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ATIC Tchem AICAR transformylase (241 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CCRF-CEM (65223 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 447.45Molecular Weight (Monoisotopic): 447.1754AlogP: 0.04#Rotatable Bonds: 11
Polar Surface Area: 221.72Molecular Species: ACIDHBA: 8HBD: 7
#RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 9#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.16CX Basic pKa: CX LogP: -0.44CX LogD: -7.16
Aromatic Rings: 2Heavy Atoms: 32QED Weighted: 0.24Np Likeness Score: 0.11

References

1. DeMartino JK, Hwang I, Connelly S, Wilson IA, Boger DL..  (2008)  Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.,  51  (17): [PMID:18686942] [10.1021/jm800555h]
2. Shih, C C, Habeck, L L LL, Mendelsohn, L G LG, Chen, V J VJ and Schultz, R M RM.  1998  Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).  [PMID:9762351]
3. Deng, Yijun and 6 more authors.  2008-08-28  Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.  [PMID:18680275]
4. Deng, Yijun Y and 7 more authors.  2009-05-14  Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.  [PMID:19371039]
5. Wang, Lei and 10 more authors.  2010-02-11  Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.  [PMID:20085328]
6. Wang, Lei and 6 more authors.  2012-02-23  Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.  [PMID:22243528]
7. Wang, Yiqiang and 7 more authors.  2013-11-14  Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.  [PMID:24111942]
8. Golani, Lalit K and 9 more authors.  2014-10-09  Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.  [PMID:25234128]
9. Wang, Yiqiang and 7 more authors.  2015-02-12  Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.  [PMID:25602637]
10. Wang, Lei and 16 more authors.  2015-09-10  6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.  [PMID:26317331]
11. Golani, Lalit K and 19 more authors.  2016-09-08  Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.  [PMID:27458733]
12. Ravindra, Manasa and 11 more authors.  2018-03-08  Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.  [PMID:29425443]
13. Ravindra, Manasa and 11 more authors.  2018-05-10  Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.  [PMID:29701475]

Source